Zydus Pharmaceuticals (USA) Inc recalls Bromocriptine Mesylate Capsules
- Published
- 26 Nov 2025
- Units affected
- 36,624 bottles
- Agency
- FDA
- Country
- United States
The hazard
Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06
- Brand / company
- Zydus Pharmaceuticals (USA) Inc
- Codes / lots
- Lot #: M313934, M313935, M315615, Exp. Date Nov 2025; M316809 , Exp. Date Dec-25; M405765, M405763, M405764, Exp. Date Apr-26; M414999, M414241, M414307, M414305, Exp. Date Oct-26
- Distribution
- Nationwide in the USA
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 26 Nov 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.